BioCentury
ARTICLE | Clinical News

MRG-106: Phase I started

March 7, 2016 8:00 AM UTC

miRagen began an open-label, U.S. Phase I trial of MRG-106 in about 25 patients. The first part will evaluate up to 5 intratumoral injections of MRG-106 over up to 15 days and determine the dose in th...